Treg engineers take aim at autoimmunity

Elie Dolgin • November 9, 2021

Companies are deploying regulatory T cells, equipped with CAR and TCR constructs, to suppress immunity — locally and for the long term.

Engineered adoptive T-cell therapies have already transformed the treatment of blood cancers. Now, several startups hope to harness the power of regulatory T cells (Tregs) to suppress immune responses and offer tolerance to transplant recipients, or to control the inflammation driving autoimmune disorders.


Continue reading at Nature Biotechnology.

Blue and gold fibrous texture in the shape of brain
By Elie Dolgin June 30, 2025
AI and real-time neural feedback could transform treatments.
Damaged 15th century painting by the Master of the Prado Adoration of the Magi
By Elie Dolgin June 12, 2025
Pixels meet paint, as a digital “mask” conceals damage on a 15th-century painting.